- Trial phase
- Phase 3
- Time to market
- Phase 3 trials started in August-September 2026 with estimated primary completion around July 2029 for the COPD studies and similar timelines for asthma and nasal polyps. If successful, a regulatory filing would likely follow in 2029-2030, with potential approval in the 2030-2031 timeframe.
- Why 4/10
- The next hard, dated catalysts are the Phase 3 primary completion dates (~July 2029 for the COPD trials, similar timelines for asthma and nasal polyps), which are more than two years away. No PDUFA, pivotal readout or Advisory Committee date is scheduled within the next 12 months. GSK is a large diversified pharma, so even a successful Phase 3 readout in ~2029 would be one data point among many. ImpactScore is 4 per the default floor for an early-stage Phase 3 asset at a large cap with no near-term binary.
Felcorekibart's Phase 3 PERSIST programme (six trials across COPD, asthma and nasal polyps) began enrollment in August-September 2026, with primary completion estimated around mid-2029. No top-line data, regulatory submission or PDUFA date is scheduled within the next 12 months, so the drug is not a near-term price catalyst for GSK. Investors should watch for any Phase 2 dose-finding data from the earlier asthma study (NCT05593250) as the next potential readout, but that trial's status is active/not recruiting with no posted results yet.
Price Chart
Executive Summary
Felcorekibart (GSK5784283, also known as AIO-001 and SHR-1905) is a long-acting, twice-yearly injectable antibody that blocks the inflammatory protein TSLP, making it a direct competitor to AstraZeneca/Amgen's Tezspire (tezepelumab). Originally developed by China's Jiangsu Hengrui, it was licensed to Aiolos Bio and then acquired by GSK in February 2024 for $1B upfront plus up to $400M in milestones. In 2026, GSK launched the broad PERSIST Phase 3 programme of six pivotal trials across COPD, uncontrolled asthma, and chronic rhinosinusitis with nasal polyps, all of which began enrollment in August-September 2026. Primary completion is estimated around mid-2029, meaning no near-term binary catalyst exists. For GSK as a large cap, felcorekibart is one of several pipeline assets with long-term potential but no near-term share-price impact.
How It Works
Felcorekibart is a laboratory-made antibody (a 'biologic' drug) that blocks a protein called TSLP. TSLP is released by cells lining the lungs and airways when they encounter triggers like allergens, viruses or pollution. It acts like an 'alarm signal' that starts a chain reaction of inflammation. By blocking TSLP, felcorekibart aims to prevent this inflammatory cascade before it begins, which could reduce asthma attacks and COPD flare-ups. The drug is designed to be long-acting, potentially requiring injections only twice a year.
Trial Status
GSK initiated six Phase 3 PERSIST trials in mid-2026: PERSIST COPD-1 and COPD-2 (624 patients each, started Aug-Sep 2026); PERSIST ASTHMA-1 (514 patients, started Aug 2026) and ASTHMA-2; and PERSIST CRSwNP-1 and CRSwNP-2 (218 patients each, started Sep 2026). All trials are actively recruiting. An earlier Phase 2 dose-finding study (NCT05593250, originally SHR-1905) in severe uncontrolled asthma is listed as active but no longer recruiting, with no published results.
The Two-Sided Case
Upcoming Catalysts
- Potential publication of Phase 2 dose-finding data from the earlier SHR-1905 asthma study (NCT05593250), though no timeline is announced
- Initiation of any remaining PERSIST trials (ASTHMA-2 already registered but start details less clear)
- Regulatory updates on the TSLP inhibitor class, especially Tezspire label expansions into COPD and nasal polyps that could set precedent
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report